Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | BRAF | P15056 | 1/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.65 |
| ▸ | BTK | Q06187 | 5/20 | 0.65 |
| ▸ | JAK3 | P52333 | 3/20 | 0.65 |
| ▸ | KIT | P10721 | 2/20 | 0.65 |
| ▸ | SRC | P12931 | 2/20 | 0.65 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.65 |
| ▸ | ITK | Q08881 | 2/20 | 0.65 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.65 |
| ▸ | CIT | O14578 | 1/20 | 0.65 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.65 |
| ▸ | GAK | O14976 | 1/20 | 0.65 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.65 |
| ▸ | STK17B | O94768 | 1/20 | 0.65 |
| ▸ | STK10 | O94804 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487207 | 1.00 | EGFR (0.66) | EGFRKDRBRAFERBB2BTK | |
| SCHEMBL27727371 | 0.84 | EGFR (0.65) | EGFRKDRBRAFERBB2BTK | |
| SCHEMBL14127461 | 0.81 | EGFR (0.45) | EGFRKDRBRAFERBB2BTK | |
| SCHEMBL1151056 | 0.81 | EGFR (0.82) | EGFRKDRBRAFERBB2BTK | |
| Hydrochloric Acid SCHEMBL15565027 | 0.80 | EGFR (0.81) | EGFRKDRBRAFERBB2BTK | |
| SCHEMBL12694361 | 0.79 | EGFR (1.00) | EGFRKDRBRAFERBB2BTK | |
| SCHEMBL5040071 | 0.79 | EGFR (0.61) | EGFRKDRBRAFERBB2BTK | |
| SCHEMBL3520111 | 0.79 | EGFR (0.72) | EGFRKDRERBB2BTKJAK3 | |
| Canertinib SCHEMBL29655741 | 0.79 | EGFR (1.00) | EGFRKDRERBB2BTKJAK3 | |
| Canertinib SCHEMBL29368458 | 0.79 | EGFR (1.00) | EGFRKDRERBB2BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347589-A2 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS | Redx Pharma Plc (GB) | 2024-04-10 | — | — | EP | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2367821-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| CN-101360736-A | L-alanine derivatives | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | disclosed |
| EP-1879886-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119146-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | PRKCB, PNCK, PACSIN2 | EGFR 1534/4885KDR 1942/4885BRAF 172/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | EGFR 815/4885KDR 1368/4885BRAF 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.